A sesterterpenoid derivative alleviates ulcerative colitis through targeting ProRS to suppress the NLRP3 inflammasome
A new small molecule that blocks the NLRP3 inflammasome via ProRS could point to future drug strategies for ulcerative colitis — a pathway involved in intestinal inflammation that matters to people with IBD. This is...